Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Kwang Yeon Carol Lee

Nurse Practitioner, Acute Care Orange, CA Nurse Practitioner

NPI 1164022448 CMS profile 11137277

101 The City Dr S, Orange, CA 92868

Open in the dashboard

General payments

$5,081

235 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Kwang Yeon Carol Lee of Orange, CA is reported in the CMS Open Payments database as having received $5,081 across 235 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Nurse Practitioner, Acute Care profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,310 53
2024 General $1,886 96
2023 General $1,396 71
2022 General $391 12
2021 General $97 3

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kwang Yeon Carol Lee
  • Nurse Practitioner, Acute Care median
  • Middle half of Nurse Practitioner, Acute Care
  • National median

In program year 2025, general payments to Kwang Yeon Carol Lee were reported at $1,310. Among 11,827 Nurse Practitioner, Acute Care profiles paid that year, the median was $152 and the middle half received between $48 and $458.

Show as a table
Year Kwang Yeon Carol Lee Nurse Practitioner, Acute Care median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $97 $123 $38–$327 $132
2022 $391 $130 $44–$369 $149
2023 $1,396 $144 $49–$410 $160
2024 $1,886 $146 $48–$433 $164
2025 $1,310 $152 $48–$458 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $797 38 payments
  2. Novartis Pharmaceuticals Corporation $725 53 payments
  3. Boehringer Ingelheim Pharmaceuticals, Inc. $676 24 payments
  4. Bayer HealthCare Pharmaceuticals Inc. $519 23 payments
  5. Janssen Pharmaceuticals, Inc $372 15 payments
  6. Lexicon Pharmaceuticals, Inc. $290 12 payments
  7. AstraZeneca Pharmaceuticals LP $267 8 payments
  8. Merck Sharp & Dohme Corporation $227 9 payments
  9. Amgen Inc. $223 10 payments
  10. Pfizer Inc. $145 6 payments
  11. Other $839 37 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $5,081 235 payments
Products named General payments · program years 2021–2025
  1. LifeVest $797 38 payments
  2. LEQVIO $675 48 payments
  3. JARDIANCE $588 21 payments
  4. Kerendia $519 23 payments
  5. XARELTO $372 15 payments
  6. ENTRESTO $316 18 payments
  7. VERQUVO $285 11 payments
  8. Repatha $223 10 payments
  9. Inpefa $167 7 payments
  10. FARXIGA $161 3 payments
  11. Other $1,406 61 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 28 drugs

Part D claims

1,339

Median for Nurse Practitioner: 389

Drug cost

$316,221

Median for Nurse Practitioner: $21,885

Branded share of claims

30.3%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Entresto Sacubitril/Valsartan Brand 96 $88,015
Jardiance Empagliflozin Brand 49 $44,163
Eliquis Apixaban Brand 37 $41,332
Inpefa Sotagliflozin Brand 66 $40,982
Kerendia Finerenone Brand 31 $34,028
Repatha Sureclick Evolocumab Brand 40 $24,828
Xarelto Rivaroxaban Brand 25 $23,951
Valsartan Generic 72 $3,464
Omega-3 Acid Ethyl Esters Generic 42 $2,747
Rosuvastatin Calcium Generic 135 $2,484

The 10 drugs with the highest cost, of 28 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 14 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $492
$492 49 —
LEQVIO
  • Novartis Pharmaceuticals Corporation $215
$215 — —
XARELTO
  • Janssen Pharmaceuticals, Inc $140
$140 25 —
Kerendia
  • Bayer HealthCare Pharmaceuticals Inc. $139
$139 31 —
Arcalyst
  • Kiniksa Pharmaceuticals International, plc $132
$132 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 14 in the dashboard with a free account

Records

235 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record